Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) antigen (propiolactone inactivated) (unii: 6f59dl4eet) (influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:qwb7m7p3k9), influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) antigen (propiolactone inactivated) (unii: y9cjf75rbv) (influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:lw2jc76p6m), influenza b virus b/victoria/705/2 - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11] ) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

merck sharp & dohme llc - streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 54ec0se5pz) (streptococcus pneumoniae type 1 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:54ec0se5pz), streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen (unii: 2vf3v7175u) (streptococcus pneumoniae type 3 capsular polysaccharide diphtheria crm197 protein conjugate antigen - unii:2vf3v7175u), streptococcus pneumoniae type - vaxneuvance™ is indicated for active immunization for the prevention of invasive disease caused by streptococcus pneumoniae serotypes 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f, 22f, 23f and 33f in individuals 6 weeks of age and older. do not administer vaxneuvance to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of vaxneuvance or to diphtheria toxoid. [see description (11).] risk summary all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. there are no adequate and well-controlled studies of vaxneuvance in pregnant women. available data on vaxneuvance administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy. developmental toxicity studies have been performed in female rats administered a human dose of vaxneuvance on four

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (propiolactone inactivated) (unii: uph9lrj9hu) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:x5dyv3mm4n), influenza a virus a/darwin/6/2021 ivr-227 (h3n2) antigen (propiolactone inactivated) (unii: n4uxa9h8ka) (influenza a virus a/darwin/6/2021 ivr-227 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:zn6bmn7fsq), influenza b virus b/austria/1359417/2021 bvr-26 anti - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated b

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - recombinant respiratory syncytial virus pre-fusion f protein (unii: m739eb7427) (recombinant respiratory syncytial virus pre-fusion f protein - unii:m739eb7427) - arexvy is indicated for active immunization for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in individuals 60 years of age and older. do not administer arexvy to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of arexvy [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. arexvy is not approved for use in persons <60 years of age. in a clinical study that enrolled pregnant individuals who received an investigational unadjuvanted rsv vaccine that contained the same rsvpref3 antigen as arexvy, an increase in preterm births was observed compared to pregnant individuals who received placebo (sucrose reconstituted with saline). data in a randomized controlled clinical trial that enroll